They help regulate blood sugar, slow digestion, and signal fullness, which is why many people experience a reduced appetite and weight loss
Their findings are published today in eClinicalMedicine
Several indirect mechanisms may explain why some patients report muscle pain or weakness while taking GLP-1 medications, even in the absence of direct myotoxicity
This simple step prevents most contamination
Although preliminary regulatory-led analyses of post-marketing data have not found conclusive evidence of a causal link [14], and in the absence of evidence from large, randomised clinical trials, observational studies adequately designed to assess the comparative safety of treatments, employing an active comparator, new user design, are warranted to evaluate the risk of SIS in individuals treated with GLP-1RA
Currently, nearly 100 million people globally are affected by DR, and as the prevalence of diabetes continues to rise, this number is expected to grow, posing a significant burden on public health (82)
